SEC Form 4 · accession 0001231919-26-000656
Artiva Biotherapeutics, Inc. · ARTV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
RA Capital Healthcare Fund LP
Director · 10% Owner
RA CAPITAL MANAGEMENT, L.P.
Director · 10% Owner
Peter Kolchinsky
Director · 10% Owner
Rajeev M. Shah
Director · 10% Owner
RA Capital Nexus Fund, L.P.
Director
RA Capital Nexus Fund III, L.P.
Director
Period of report
Jun 12, 2026
Accepted (ET)
Jun 16, 2026 · 6:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001817241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jun 12, 2026 | P | 391,019 | $8.57 | A | 16,622,736 | I | See footnotes |
| Common StockF4,F2,F3 | Jun 15, 2026 | P | 15,414 | $8.99 | A | 16,638,150 | I | See footnotes |
| Common StockF5,F2,F3 | Jun 16, 2026 | P | 124,893 | $8.89 | A | 16,763,043 | I | See footnotes |
| Common StockF2,F6 | holding | — | — | — | 264,571 | I | See footnotes | |
| Common StockF2,F7 | holding | — | — | — | 826,832 | I | See footnotes | |
| Common StockF2,F8 | holding | — | — | — | 68,320 | I | See footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.31 to $8.64 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- F3Held directly by the Fund.
- F4The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.96 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F5The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.63 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F6Held directly by the Nexus Fund.
- F7Held directly by Nexus Fund III.
- F8Held directly by the Account.
Remarks
Laura Stoppel, a Principal of the Adviser, serves on the Issuer's board of directors